•J THORAC CARDIOV SUR编委 •J CANCER RES CLIN副主编 •JTO CRR副主编 [1] 1. HOWINGTON J A, BLUM M G, CHANG A C, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-base...
根据CALIBRATE-NSCLC研究、LUNGCA研究和吴一龙教授发表在在Cancer Discovery的MRD研究提示，与MRD阴性患者相比，术后MRD阳性患者具有较高的复发风险；在CALIBRATE-NSCLC研究中，纳入116例接受了手术的NSCLC患者，最终103例患者数据纳入分析；对85例患者术后1个月内单个时间节点血浆样本进行MRD检测，18例患者术后MRD阳性，与...
J THORAC CARDIOV SUR 编委、J CANCER RES CLIN 副主编,Am J Transl Res、J Thorac Dis 编委。主持国家自然科学基金重点项目及面上项目、市部级重点等多项科研项目。 参考文献: 1.2023 WCLC.P1.25-06. Real-world Primary Treatment Patterns in Stages I-III Non-Small Cell Lung Cancer P1.25. 2.2023 WCLC...
Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. Clin Lung Cancer. 2022 May;23(3):e247-e251. ...
[5] Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. Clin Lung Cancer. 2022 May...
相关研究结果已于2023年12月19日发表在《Nature Communications》期刊上,标题为“Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial”。
[24] Keller SM,Adak S,Wagner H,et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 2000;70:358-365...
[3] He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med....
9. He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021 Sep;9(9):1021-1029. ...
Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. Clinical lung cancer vol. 23,3 (2022): e247-...